PubRank

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Clinical Trial ID NCT01044654

PubWeight™ 97.42‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01044654

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010 18.88
2 ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013 11.58
3 High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013 8.40
4 A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 2011 7.93
5 Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 2011 6.90
6 Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 2015 2.56
7 Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 2012 2.02
8 Advances in targeted genome editing. Curr Opin Chem Biol 2012 1.97
9 Prospects for treatment of latent HIV. Clin Pharmacol Ther 2012 1.91
10 RNA guides genome engineering. Nat Biotechnol 2013 1.84
11 Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 2011 1.50
12 Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res 2013 1.48
13 Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 2013 1.41
14 Developing strategies for HIV-1 eradication. Trends Immunol 2012 1.38
15 Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One 2014 1.24
16 Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther 2011 1.11
17 Targeted gene disruption to cure HIV. Curr Opin HIV AIDS 2013 1.09
18 Newer gene editing technologies toward HIV gene therapy. Viruses 2013 1.07
19 Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med 2012 1.07
20 Novel approaches to inhibit HIV entry. Viruses 2012 1.00
21 T-cell therapies for HIV. Immunotherapy 2013 0.99
22 Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Res 2014 0.95
23 Creating genetic resistance to HIV. Curr Opin Immunol 2012 0.93
24 Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol 2013 0.92
25 Eradication of HIV and Cure of AIDS, Now and How? Front Immunol 2013 0.92
26 HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 2014 0.89
27 Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep 2014 0.88
28 Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol 2014 0.86
29 CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy 2013 0.85
30 State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 2014 0.84
31 HIV-1 functional cure: will the dream come true? BMC Med 2015 0.84
32 Current progress and challenges in HIV gene therapy. Future Virol 2011 0.82
33 RNA interference approaches for treatment of HIV-1 infection. Genome Med 2015 0.81
34 Stem-cell-based gene therapy for HIV infection. Viruses 2013 0.81
35 Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther 2015 0.81
36 Cell and gene therapy strategies to eradicate HIV reservoirs. Curr Opin HIV AIDS 2016 0.80
37 Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses 2013 0.80
38 Zinc Finger Nucleases: Tailor-made for Gene Therapy. Drugs Future 2012 0.79
39 The clinical applications of genome editing in HIV. Blood 2016 0.79
40 Gene therapy targeting HIV entry. Viruses 2014 0.79
41 Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system. Mol Ther Methods Clin Dev 2014 0.79
42 Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells Cloning 2015 0.78
43 Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev 2016 0.78
44 Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev 2016 0.77
45 Application of gene-editing technologies to HIV-1. Curr Opin HIV AIDS 2015 0.76
46 TALENs targeting HBV: designer endonuclease therapies for viral infections. Mol Ther 2013 0.76
47 In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci 2016 0.75
48 From hacking the human genome to editing organs. Organogenesis 2015 0.75
49 T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy 2016 0.75
50 Gene therapy's out-of-body experience. Nat Biotechnol 2016 0.75
Next 100